grafa.comOct 13$JNJ

Johnson & Johnson Reports $25.4B Third Quarter Sales Growth

Johnson & Johnson reported Q3 2026 sales of $25.4B, up 5.9% YoY. Adjusted EPS was $2.59, while GAAP EPS was $0.09 due to special charges. The company raised its full-year guidance to $101.2B in sales and $11.10 in adjusted EPS. Recent product developments include OTTAVA, IMAAVY, and RYBREVANT FASPRO.

Original reporting

grafa.com

Published Oct 13, 2026, 4:46 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 13, 2026, 7:13 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Johnson & Johnson Reports $25.4B Third Quarter Sales Growth — source image — Source · grafa.com

Decision brief

The 30-second read

$JNJBullishMed

Why it matters

Raised full-year guidance and positive operational growth are the key decision inputs for positioning, while litigation and deal-related items add uncertainty around earnings quality.

Market read

This is a company-specific earnings and guidance update with explicit full-year targets, making it actionable for near-term earnings expectation and valuation adjustments.

What to watch

Product authorization and approvals (OTTTAVA, IMAAVY, RYBREVANT FASPRO priority review) could be incremental, but traders may discount them if they do not translate into near-term revenue growth.

Relevance 8/10Novelty 7/10Timing: reported third-quarter results and raised full-year guidance (today)

Background

The company’s Q3 print includes both adjusted earnings and GAAP results affected by litigation-related charges and acquisition/collaboration impacts.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JNJBullishHigh confidence

Context

Johnson & Johnson reported Q3 2026 sales of $25.4B (+5.9% YoY) and raised full-year guidance to ~$101.2B sales and $11.10 adjusted EPS.

Expected impact

Likely upward bias as traders price in higher full-year sales and adjusted EPS, partially offset by litigation and acquisition-related GAAP noise.

Evidence & confidence

The article provides specific, company-issued quarterly results plus explicit full-year guidance increases, which are direct drivers for earnings expectations and valuation.

Market effects

Sector

Large-cap pharma and healthcare peers may see read-through on demand and pipeline momentum, but the main signal is JNJ-specific guidance.

Regional

Primarily US large-cap sentiment; limited direct regional spillover beyond healthcare complex.

Global

Global healthcare investors may adjust sector risk premia modestly given JNJ’s multinational footprint and guidance change.

Counterpoint

What could challenge this read

GAAP EPS is heavily distorted by litigation and acquisition-related charges, so the market may focus on whether adjusted metrics can sustain without further legal or integration costs.

Key entities

company
Johnson & Johnson
Reported Q3 2026 sales growth and increased full-year 2026 guidance; highlighted product authorizations and approvals.
acquisition
Firefly Bio
Acquisition referenced as impacting GAAP and adjusted EPS in the quarter.
collaboration
Sail Biomedicines
Strategic collaboration referenced as impacting adjusted EPS in the quarter.
litigation
Talc litigation resolution
Proposed resolution referenced as driving a one-time GAAP special charge.

Read at source ← All news

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.comNov 4

$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.comNov 2

$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ieNov 2

$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.comNov 2

$JNJMedAI 8/10

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

rttnews.comNov 2

$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.comNov 2